LIR Life Sciences Corp. is a biopharmaceutical company focused on developing innovative transdermal and sublingual drug delivery systems, particularly targeting obesity and metabolic disorders. Founded in 2024 and headquartered in Vancouver, Canada, the company aims to improve accessibility and patient experience by creating scalable, affordable therapies that mimic GLP-1, a hormone involved in appetite and blood sugar regulation. Its core product development includes a transdermal patch designed as an alternative to injectable obesity treatments, potentially enhancing treatment adherence and cost-efficiency. LIR Life Sciences holds a significant role in the biotechnology and medical research sector by addressing the global health challenge of obesity with novel drug delivery methods based on established compounds and proven science. Under the leadership of CEO Dr. Edward Mills, a recognized clinical research expert, the company is advancing solutions intended for both developed and emerging markets, contributing innovation within the pharmaceutical space focused on metabolic health.